NewAmsterdam Pharma Co N.V (NAMS) Income towards Parent Company: 2023-2025
Historic Income towards Parent Company for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$72.0 million.
- NewAmsterdam Pharma Co N.V's Income towards Parent Company fell 332.54% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 11.15%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.54% down from last year.
- NewAmsterdam Pharma Co N.V's Income towards Parent Company amounted to -$72.0 million in Q3 2025, which was down 314.68% from -$17.4 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma Co N.V's Income towards Parent Company registered a high of -$16.6 million during Q3 2024, and its lowest value of -$93.8 million during Q1 2024.
- Its 3-year average for Income towards Parent Company is -$49.8 million, with a median of -$42.0 million in 2023.
- Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 64.68% in 2024, then tumbled by 332.54% in 2025.
- Over the past 3 years, NewAmsterdam Pharma Co N.V's Income towards Parent Company (Quarterly) stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then slumped by 332.54% to -$72.0 million in 2025.
- Its Income towards Parent Company was -$72.0 million in Q3 2025, compared to -$17.4 million in Q2 2025 and -$39.5 million in Q1 2025.